Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

Company Overview - Achieve Life Sciences, Inc. is a late-stage pharmaceutical company focused on the global development and commercialization of cytisinicline for treating nicotine dependence [1][3] - The company is participating in two upcoming investor conferences: Jefferies London Healthcare Conference on November 19-21, 2024, and Piper Sandler 36th Annual Healthcare Conference on December 3-5, 2024 [2] Industry Context - Tobacco use is the leading cause of preventable death, responsible for over 8 million deaths globally and nearly 500,000 deaths annually in the United States [3] - Approximately 29 million adults smoke combustible cigarettes, and over 11 million adults in the U.S. use e-cigarettes [3][4] - In 2024, around 1.6 million middle and high school students in the U.S. reported using e-cigarettes [3] Product Information - Cytisinicline is a plant-based alkaloid with a high binding affinity to nicotinic acetylcholine receptors, aimed at treating nicotine addiction by reducing cravings and satisfaction associated with nicotine products [4] - Cytisinicline has received Breakthrough Therapy designation from the FDA to address the critical need for e-cigarette cessation treatments [3][4]